Peptide Cancer Vaccine Market Clinical Trials Insight Report: Over 50 Peptide Cancer Vaccines in Clinical Trials [Yahoo! Finance]
SELLAS Life Sciences Group, Inc. (SLS)
Last sellas life sciences group, inc. earnings: 11/14 04:41 pm
Check Earnings Report
US:NYSE Investor Relations:
sellaslifesciences.com/investors/overview/default.aspx
Company Research
Source: Yahoo! Finance
Key prospects lie in multivalent neoantigen-based vaccines, promising late-stage clinical trials, and advancing technology platforms. Growing collaborations and personalized therapies are driving market potential. Dublin, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The "Peptide Cancer Vaccine Market Opportunity, Technology Platforms & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. Cancer remains among the most common causes of death globally, and current therapies like chemotherapy and radiation are frequently associated with serious side effects and inconsistent response rates. In such an instance, peptide based cancer vaccines could offer a viable option for targeted immune mediated cancer destruction with less toxicity. Such vaccines utilize tumor specific or neoantigenic peptides to generate extremely specific T-cell responses with the precision of immunotherapy without the intricacy of cell or viral vector platforms. This report is aimed at
Show less
Read more
Impact Snapshot
Event Time:
SLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLS alerts
High impacting SELLAS Life Sciences Group, Inc. news events
Weekly update
A roundup of the hottest topics
SLS
News
- SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswire
- SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual MeetingGlobeNewswire
- SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross ProceedsGlobeNewswire
- SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities ForumGlobeNewswire
SLS
Sec Filings
- 12/5/25 - Form 4
- 12/5/25 - Form 4
- 12/5/25 - Form 4
- SLS's page on the SEC website